Document is current
Any future updates will be listed below
-
Authors
Andrysik, Zdenek
Sullivan, Kelly D.
Kieft, Jeffrey S.
Espinosa, Joaquin M. http://orcid.org/0000-0001-9048-1941
-
Funding
Funding for this research was provided by:
Cancer League of Colorado (AWD-203708-AZ)
American Cancer Society (16-184-56)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5R01CA117907)
U.S. Department of Health & Human Services | National Institutes of Health (R35GM118070)
- License Information
-
More Information
Article History
Received: 14 January 2022
Accepted: 17 November 2022
First Online: 1 December 2022
Competing interests
: J.M.E. has provided consulting services for Elli Lily and Co. and Gilead Sciences Inc. and serves in the advisory board of Perha Pharmaceuticals. J.M.E. and Z.A. have applied as co-inventors in a provisional patent for employing dual activation of the p53 and ISR networks in cancer therapy (U.S. Provisional Patent Application 63/356,432). The other authors declare no competing interests.
